Romeg Therapeutics

What Romeg Therapeutics does

Romeg Therapeutics, LLC is a privately held, revenue-generating specialty pharmaceutical company headquartered in Woburn, Massachusetts. The company is focused on reformulating well-characterized, FDA-approved molecules into novel dosage forms — primarily liquid and oral solutions — to address precision dosing and administration challenges in patient populations with unmet clinical needs. Its core commercial product is Gloperba (colchicine oral solution 0.6mg/5mL), the first and only FDA-approved liquid oral colchicine formulation, indicated for prophylaxis of gout flares in adults and launched in the US in June 2024. Additional pipeline assets include a proprietary pilocarpine oral solution for xerostomia (covered by US Patent No. 11,564,909), two active programs targeting Sjogren's syndrome, and RMG-03, a Phase 2-stage candidate for COVID-19.

Romeg operates a capital-light, licensing-based business model rather than direct commercialization. The company develops formulations, secures FDA approvals (notably via the 505(b)(2) NDA pathway), and licenses commercialization rights to third parties. Its primary partner, Scilex Holding Company, holds exclusive worldwide rights to Gloperba (US-only rights originally granted in June 2022, expanded to worldwide in January 2025) and handles all manufacturing, marketing, distribution, and sales through its US wholesaler and pharmacy network. Romeg generates revenue from licensing fees and royalties on partner product sales, while retaining ownership of the underlying intellectual property and formulation know-how. The company is founder-led (Indu Muni, Ph.D., Founder/Chairman/CEO; Naomi Vishnupad, Ph.D., CSO) with a lean team of 1–10 employees, and discloses no institutional funding rounds.

Name

Romeg Therapeutics

Legal name

Romeg Therapeutics, LLC

Website

https://romegrx.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Romeg Therapeutics is a privately held specialty pharmaceutical company that reformulates approved molecules into novel dosage forms, licensing them to commercialization partners. Its lead product, Gloperba, is the first FDA-approved liquid oral colchicine for gout flare prophylaxis, commercialized by Scilex in the US.

Ownership category

akta.pro rank

Headquarters

HQ city

Woburn

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Licensing and Royalty Revenue: Romeg develops pharmaceutical products and licenses commercialization rights to partners like Scilex Holding Company. The company receives licensing fees and ongoing royalties from product sales. The partnership with Scilex for Gloperba was originally exclusive for US rights (June 2022) and was later amended to include worldwide rights (January 2025).
2. Product Development and Approval: Revenue generated through FDA approvals and subsequent licensing deals for novel formulations developed by Romeg, such as Gloperba which was made available in the United States in 2020.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Romeg Therapeutics develops novel dosage forms (primarily liquid oral formulations) of well-characterized molecules to address unmet clinical needs. Its commercial product is Gloperba (colchicine oral solution 0.6mg/5mL), the first and only FDA-approved liquid oral version of colchicine for prophylactic treatment of gout flares in adults. The pipeline includes a proprietary pilocarpine oral solution for xerostomia and two programs targeting Sjogren's syndrome.

Product overview

Romeg Therapeutics is a privately held specialty pharmaceutical company focused on developing novel dosage forms of existing approved drugs. The company's commercial product portfolio centers on Gloperba (colchicine oral solution), the only FDA-approved liquid formulation for prophylactic treatment of gout flares in adults, which is marketed and distributed by commercial partner Scilex Pharmaceuticals following a license agreement. Romeg's development pipeline includes two active programs targeting Sjogren's syndrome, as well as a proprietary pilocarpine oral solution for xerostomia. The company's strategy emphasizes reformulating well-characterized molecules into innovative new formulations to address unmet clinical needs, with pipeline efforts focused on rheumatologic and cardiac inflammatory diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Gloperba (Colchicine Oral Solution) FDA-approved colchicine oral solution (0.6mg/5mL) for the prophylactic treatment of gout flares in adults. It is the only FDA-approved liquid oral formulation of colchicine, providing precision dosing flexibility for at-risk patient populations including those with renal impairment or difficulty swallowing pills. Launched at $595 per 150mL bottle.
• Pilocarpine Oral Solution Proprietary formulation of pilocarpine for the treatment of xerostomia (dry mouth) in patients including those with Sjogren's Syndrome and head/neck radiation therapy who have difficulty swallowing tablets. Protected by US Patent No. 11,564,909.
• Sjogren's Syndrome Pipeline Programs

Quantifiable outcome

• First and only FDA-approved liquid colchicine formulation
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Scilex Holding CompanycoreChannel Partner/ Reseller/ Distributor · 14 June 2022Scilex Holding Company holds exclusive license rights to commercialize Gloperba. Original agreement (June 2022) granted US-only rights; amended in January 2025 to include worldwide rights. Scilex handles all commercialization, marketing, and distribution activities including direct network to national/regional wholesalers and pharmacies. Romeg receives licensing fees and royalties from product sales.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• TerSera Therapeutics: Mid-sized specialty pharmaceutical company focused on acquiring, developing, and commercializing niche branded prescription products, often leveraging reformulation or 505(b)(2) pathways to differentiate.
• Harrow Health: Small-cap specialty pharmaceutical company focused on niche therapeutic categories with proprietary and reformulated products, comparable in size and strategy to Romeg.
• Collegium Pharmaceutical: Specialty pharmaceutical company focused on abuse-deterrent and reformulated small-molecule products, using a similar development-plus-partner commercialization model in differentiated dosage forms.
• ANI Pharmaceuticals: Specialty and generic pharmaceutical company that acquires, develops, and markets niche branded prescription products, often using 505(b)(2) pathways to bring differentiated dosage forms to market.
• Assertio Holdings: Specialty pharma (formerly Depomed) that builds franchises around reformulated, differentiated small-molecule dosage forms with focused physician promotion, mirroring Romeg's 505(b)(2) reformulation strategy.

Broad incumbents

• Endo International: Specialty and generic pharmaceutical company with a portfolio that includes colchicine generics and other reformulated small molecules, overlapping with Romeg's therapeutic categories.
• Amneal Pharmaceuticals: Large specialty and generic pharmaceutical manufacturer with an established specialty branded franchise developed via 505(b)(2) reformulations; broader portfolio than Romeg but operates the same development pathway.
• Lannett Company: Generic and specialty pharmaceutical manufacturer with niche branded products developed through reformulation, comparable to Romeg's specialty pharmaceutical model but at a larger scale.
• Hikma Pharmaceuticals: Large multinational specialty and generic pharmaceutical company that both develops and manufactures reformulated small molecules, with significant US specialty branded and injectable franchises.

Others

• Scilex Holding Company: Romeg's exclusive worldwide commercialization partner for Gloperba; a specialty pharma commercializing non-opioid pain and gout products. While not a direct competitor, its commercial execution directly drives Romeg's royalty revenue.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/romeg-therapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Romeg Therapeutics